share_log

Benchmark Upgrades Emergent BioSolutions to Buy, Announces $22 Price Target

Benzinga ·  Apr 10, 2023 06:57

Benchmark analyst Robert Wasserman upgrades Emergent BioSolutions (NYSE:EBS) from Hold to Buy and announces $22 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment